PMID- 24879948
OWN - NLM
STAT- MEDLINE
DCOM- 20141104
LR  - 20220409
IS  - 1879-1891 (Electronic)
IS  - 0002-9394 (Linking)
VI  - 158
IP  - 3
DP  - 2014 Sep
TI  - Suppression of intraocular vascular endothelial growth factor during aflibercept 
      treatment of age-related macular degeneration.
PG  - 532-6
LID - S0002-9394(14)00297-9 [pii]
LID - 10.1016/j.ajo.2014.05.025 [doi]
AB  - PURPOSE: To determine the duration of suppression of aqueous humor concentrations 
      of vascular endothelial growth factor (VEGF) in eyes with neovascular age-related 
      macular degeneration (AMD) treated with aflibercept. DESIGN: Nonrandomized 
      prospective clinical study. METHODS: Twenty-seven eyes of 27 neovascular AMD 
      patients receiving intravitreal aflibercept injections on a pro re nata regimen 
      driven by spectral-domain optical coherence tomography (SD OCT) were included in 
      this study. A total of 132 aqueous humor specimens were collected before 
      intravitreal aflibercept injections and their VEGF-A concentrations assayed by 
      multiplex bead analysis. RESULTS: Mean aqueous humor VEGF concentrations before 
      treatment initiation were 90.6 +/- 37.1 pg/mL (range 23.4-190.3 pg/mL). 
      Intravitreal injection of aflibercept suppressed the aqueous VEGF concentrations 
      to below the lower limit of quantification (<4 pg/mL) in all patients. The mean 
      duration of VEGF suppression below the lower limit of quantification was >71 +/- 18 
      days. The earliest time after injection at which the VEGF concentration recovered 
      to above the lower limit of quantification was 55 days in 1 patient and >56 days, 
      the recommended aflibercept treatment interval, in 20 patients. The aqueous VEGF 
      recovery status of 6 patients was uncertain after 56 days. CONCLUSIONS: On 
      average, VEGF concentrations in the aqueous humor were suppressed below the lower 
      limit of quantification after intravitreal aflibercept injections for about 10 
      weeks. This aqueous suppression time suggests durable VEGF inhibition for most 
      patients dosed with aflibercept every 8 weeks.
CI  - Copyright (c) 2014 Elsevier Inc. All rights reserved.
FAU - Fauser, Sascha
AU  - Fauser S
AD  - Department of Ophthalmology, University Hospital of Cologne, Cologne, Germany.
FAU - Schwabecker, Viktoria
AU  - Schwabecker V
AD  - Department of Ophthalmology, University Hospital of Cologne, Cologne, Germany.
FAU - Muether, Philipp S
AU  - Muether PS
AD  - Department of Ophthalmology, University Hospital of Cologne, Cologne, Germany. 
      Electronic address: philmuether@mac.com.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Observational Study
DEP - 20140528
PL  - United States
TA  - Am J Ophthalmol
JT  - American journal of ophthalmology
JID - 0370500
RN  - 0 (Biomarkers)
RN  - 0 (Recombinant Fusion Proteins)
RN  - 15C2VL427D (aflibercept)
RN  - EC 2.7.10.1 (Receptors, Vascular Endothelial Growth Factor)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Aqueous Humor/*metabolism
MH  - Biomarkers/metabolism
MH  - Female
MH  - Fluorescein Angiography
MH  - Follow-Up Studies
MH  - Fundus Oculi
MH  - Humans
MH  - Intravitreal Injections
MH  - Macular Degeneration/*drug therapy/metabolism/pathology
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Receptors, Vascular Endothelial Growth Factor/administration & 
      dosage/*antagonists & inhibitors/metabolism
MH  - Recombinant Fusion Proteins/*administration & dosage
MH  - Tomography, Optical Coherence
MH  - Treatment Outcome
MH  - Visual Acuity
EDAT- 2014/06/01 06:00
MHDA- 2014/11/05 06:00
CRDT- 2014/06/01 06:00
PHST- 2014/04/03 00:00 [received]
PHST- 2014/05/21 00:00 [revised]
PHST- 2014/05/22 00:00 [accepted]
PHST- 2014/06/01 06:00 [entrez]
PHST- 2014/06/01 06:00 [pubmed]
PHST- 2014/11/05 06:00 [medline]
AID - S0002-9394(14)00297-9 [pii]
AID - 10.1016/j.ajo.2014.05.025 [doi]
PST - ppublish
SO  - Am J Ophthalmol. 2014 Sep;158(3):532-6. doi: 10.1016/j.ajo.2014.05.025. Epub 2014 
      May 28.